Underactivation of the adiponectin-adiponectin receptor 1 axis in clear cell renal cell carcinoma: Implications for progression

Clinical and Experimental Metastasis

Volumn 31, Issue 2, 2014, Pages 169-183

  Kleinmann, Nir ^a,c   Duivenvoorden, Wilhelmina C M ^a,c   Hopmans, Sarah N ^a,c   Beatty, Laura K ^a,c   Qiao, Shengjun ^a   Gallino, Daniel ^a   Lhotak, Sarka ^a   Daya, Dean ^a   Paschos, Athanasios ^a,c   Austin, Richard C ^a   Pinthus, Jehonathan H ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c Department of Surgery   (Canada)

Author keywords

Adiponectin; Kidney cancer; Metabolism; Obesity

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; RAPAMYCIN; SHORT HAIRPIN RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SIZE; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; ENZYME RELEASE; GENE SILENCING; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LATENT PERIOD; LUNG WEIGHT; MALE; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADIPONECTIN; ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN KINASES; RECEPTORS, ADIPONECTIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893208819     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-013-9618-1     Document Type: Article

References (64)

1. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B (2000) Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 343(18):1305-1311
2. Diez JJ, Iglesias P (2003) The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148(3):293-300
3. Goldstein BJ, Scalia R (2004) Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89(6):2563-2568
4. Gavrila A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, Orlova C, Mantzoros CS (2003) Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 88(10):4823-4831
5. Trujillo ME, Scherer PE (2005) Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257(2):167-175
6. Yamauchi T, Hara K, Kubota N, Terauchi Y, Tobe K, Froguel P, Nagai R, Kadowaki T (2003) Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord 3(4):243-254
7. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106(22):2767-2770
8. Chandran M, Phillips SA, Ciaraldi T, Henry RR (2003) Adiponectin: more than just another fat cell hormone? Diabetes Care 26(8):2442-2450
9. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S (2003) Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9(15):5699-5704
10. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS (2005) Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97(22):1688-1694
11. Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La Vecchia C (2004) Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 89(3):1160-1163
12. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S (2005) Prostate cancer and adiponectin. Urology 65(6):1168-1172
13. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, Mantzoros CS (2007) Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 16(2):308-313
14. Pinthus JH, Kleinmann N, Tisdale B, Chatterjee S, Lu JP, Gillis A, Hamlet T, Singh G, Farrokhyar F, Kapoor A (2008) Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. Eur Urol 54(4):866-873
15. Horiguchi A, Ito K, Sumitomo M, Kimura F, Asano T, Hayakawa M (2008) Decreased serum adiponectin levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 38(2):106-111
16. Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS (2007) Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer 120(7):1573-1578
17. Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23(5):1028-1043
18. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, Cao Y (2004) Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 101(8):2476-2481
19. Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89(17):1260-1270
20. Cho NH, Shim HS, Rha SY, Kang SH, Hong SH, Choi YD, Hong SJ, Cho SH (2003) Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol 44(5):560-566
21. Abdel-Wahed MM, Asaad NY, Aleskandarany M (2004) Expression of matrix metalloproteinase-2 in renal cell carcinoma. J Egypt Natl Cancer Inst 16(3):168-177
22. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert RH (1998) Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 160(5):1914-1918
23. Cumming AP, Hopmans SN, Vukmirovic-Popovic S, Duivenvoorden WC (2011) PSA affects prostate cancer cell invasion in vitro and induces an osteoblastic phenotype in bone in vivo. Prostate Cancer Prostatic Dis 14(4):286-294
24. Vukmirovic-Popovic S, Escott NG, Duivenvoorden WC (2008) Presence and enzymatic activity of prostate-specific antigen in archival prostate cancer samples. Oncol Rep 20(4):897-903
25. Duivenvoorden WC, Hirte HW, Singh G (1999) Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis 17(1):27-34
26. Duivenvoorden WC, Hirte HW, Singh G (2001) Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study. Int J Cancer 91(6):857-862
27. Lhotak S, Elavathil LJ, Vukmirovic-Popovic S, Duivenvoorden WC, Tozer RG, Singh G (2001) Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma. Clin Exp Metastasis 18(6):463-470
28. Duivenvoorden WC, Beatty LK, Lhotak S, Hill B, Mak I, Paulin G, Gallino D, Austin RC, Pinthus JH (2013) Underexpression of the tumor suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo. Br J Cancer 108(2):327-333
29. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423(6941):762-769
30. Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26(3):439-451
31. Hardie DG (2008) AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes 32(Suppl 4):S7-S12
32. Robb VA, Karbowniczek M, Klein-Szanto AJ, Henske EP (2007) Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 177(1):346-352
33. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300
34. Patard JJ, Rioux-Leclercq N, Fergelot P (2006) Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49(4):633-643
35. Kroog GS, Motzer RJ (2008) Systemic therapy for metastatic renal cell carcinoma. Urol Clin N Am 35(4):687-701
36. Miller RE, Larkin JM (2009) Combination systemic therapy for advanced renal cell carcinoma. Oncologist 14(12):1218-1224
37. Bastien L, Culine S, Paule B, Ledbai S, Patard JJ, de la Taille A (2009) Targeted therapies in metastatic renal cancer in. BJU Int 103(10):1334-1342
38. Chou SH, Tseleni-Balafouta S, Moon HS, Chamberland JP, Liu X, Kavantzas N, Mantzoros CS (2010) Adiponectin receptor expression in human malignant tissues. Horm Cancer 1(3):136-145
39. Pfeiler G, Hudelist G, Wulfing P, Mattsson B, Konigsberg R, Kubista E, Singer CF (2010) Impact of AdipoR1 expression on breast cancer development. Gynecol Oncol 117(1):134-138
40. Barresi V, Grosso M, Giuffre G, Tuccari G, Barresi G (2009) The expression of adiponectin receptors Adipo-R1 and Adipo-R2 is associated with an intestinal histotype and longer survival in gastric carcinoma. J Clin Pathol 62(8):705-709
41. Byeon JS, Jeong JY, Kim MJ, Lee SM, Nam WH, Myung SJ, Kim JG, Yang SK, Kim JH, Suh DJ (2010) Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer 127(12):2758-2767
42. Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, Kim SE, Lee GY, Lee JW, Jung SA, Chung HY, Jeong S, Kim JB (2010) Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol 24(7):1441-1452
43. Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, Sharma D (2009) LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 28(29):2621-2633
44. Arditi JD, Venihaki M, Karalis KP, Chrousos GP (2007) Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res 39(1):9-13
45. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R (2006) Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 345(1):271-279
46. Dos Santos E, Benaitreau D, Dieudonne MN, Leneveu MC, Serazin V, Giudicelli Y, Pecquery R (2008) Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep 20(4):971-977
47. Moon HS, Chamberland JP, Aronis K, Tseleni-Balafouta S, Mantzoros CS (2011) Direct role of adiponectin and adiponectin receptors in endometrial cancer: in vitro and ex vivo studies in humans. Mol Cancer Ther 10(12):2234-2243
48. Sugiyama M, Takahashi H, Hosono K, Endo H, Kato S, Yoneda K, Nozaki Y, Fujita K, Yoneda M, Wada K, Nakagama H, Nakajima A (2009) Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol 34(2):339-344
49. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN (2008) The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila PA) 1(5):369-375
50. Bub JD, Miyazaki T, Iwamoto Y (2006) Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 340(4):1158-1166
51. Ishikawa M, Kitayama J, Yamauchi T, Kadowaki T, Maki T, Miyato H, Yamashita H, Nagawa H (2007) Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci 98(7):1120-1127
52. Fukata S, Inoue K, Kamada M, Kawada C, Furihata M, Ohtsuki Y, Shuin T (2005) Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer 103(5):931-942
53. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, Hardie DG (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2(4):28
54. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271-2281
55. Al-Saleem T, Wessner LL, Scheithauer BW, Patterson K, Roach ES, Dreyer SJ, Fujikawa K, Bjornsson J, Bernstein J, Henske EP (1998) Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 83(10):2208-2216
56. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr (2003) TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4(2):147-158
57. Romanelli A, Dreisbach VC, Blenis J (2002) Characterization of phosphatidylinositol 3-kinase-dependent phosphorylation of the hydrophobic motif site Thr(389) in p70 S6 kinase 1. J Biol Chem 277(43):40281-40289
58. Chiang GG, Abraham RT (2005) Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 280(27):25485-25490
59. Linehan WM, Srinivasan R, Schmidt LS (2010) The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7(5):277-285
60. Tong WH, Sourbier C, Kovtunovych G, Jeong SY, Vira M, Ghosh M, Romero VV, Sougrat R, Vaulont S, Viollet B, Kim YS, Lee S, Trepel J, Srinivasan R, Bratslavsky G, Yang Y, Linehan WM, Rouault TA (2011) The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 20(3):315-327
61. Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF 3rd, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR Jr, Linehan WM, Schmidt LS, Zbar B (2006) Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci USA 103(42):15552-15557
62. Vazquez-Martin A, Oliveras-Ferraros C, del Barco S, Martin-Castillo B, Menendez JA (2009) The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol 20(3):592-595
63. Konturek PC, Burnat G, Rau T, Hahn EG, Konturek S (2008) Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci 53(3):597-605
64. Miyazaki T, Bub JD, Uzuki M, Iwamoto Y (2005) Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun 333(1):79-87